A more traditional kind of COVID-19 vaccine is a step closer to becoming the fourth option for U.S. adults.
American adults who haven't yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
FDA's vaccine chief Dr. Peter Marks said another choice in the U.S. may entice at least some vaccine holdouts -- whatever their reason -- to consider rolling up their sleeves. The FDA advisory panel voted that the benefits of two primary Novavax doses outweigh its risks - but they had a lot of questions about the shots' role at this point in the pandemic.
And while"this vaccine has incredible potential," there's no clear evidence yet of how well it works against the more contagious omicron variant and its siblings, added fellow adviser Dr. Bruce Gellin of the Rockefeller Foundation. This type of vaccine"we think generates a broad immune response against a broad array of variants," he told the FDA advisory panel.
Novavax argued there were other potential causes for the reports. Other infections including COVID-19 also can cause heart inflammation. The company said more than 744,000 vaccinations in other countries so far support the shots' safety.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax Covid-19 Vaccine Faces FDA Advisers’ ScrutinyThe outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern.
Read more »
FDA advisers meeting on Novavax, a latecomer in COVID-19 vaccine raceA federal advisory committee will vote on whether regulators should authorize a COVID-19 vaccine made by Novavax. From The New York Times.
Read more »
FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's NovavaxDevelopment of the vaccine, from Novavax, a Gaithersburg, Maryland-based company, was started at the same time as others in 2020, but the company struggled to produce its shot in large quantities.
Read more »
FDA advisers back Novavax COVID-19 shots as new US optionNovavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
Read more »
FDA panel greenlights Novavax COVID-19 vaccineFDA's vaccine chief said another choice in the U.S. may entice at least some vaccine holdouts - whatever their reason - to consider rolling up their sleeves. FOX13
Read more »
FDA advisers vote to recommend Novavax Covid-19 vaccineAdvisers signaled interest in making available a vaccine made with a technology different from the messenger RNA shots that have dominated the U.S. immunization arsenal against the disease.
Read more »